fosaprepitant / Generic mfg. - LARVOL DELTA

A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial. (PubMed, Cancer Chemother Pharmacol) - "OERIS is a promising, convenient, safe anti-emetic therapy effective for acute and delayed phases (lasts for 5-days) of CINV in patients receiving chemotherapy with a single dose."

Journal • P1 data • PK/PD data • Chemotherapy-Induced Nausea and Vomiting • Oncology

QLM2010-301: To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. (clinicaltrials.gov) - P3 | N=665 | Completed | Sponsor: Qilu Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Oct 2025 | Trial primary completion date: Dec 2025 ➔ Aug 2025

Trial completion • Trial completion date • Trial primary completion date • Chemotherapy-Induced Nausea and Vomiting

CINV GUIDELINE CONCORDANT CARE: HIGH DOSE METHOTREXATE (SIOP 2025) - "The most frequent antiemetics prescribed included aprepitant, fosaprepitant, ondansetron and palonosetron. Guideline concordant care is fundamental to optimising antiemetic prophylaxis, promoting a standardised prescribing approach that aligns with the emetic potential of the chemotherapy to ultimately improve quality of life."

CINV • Discordant • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chemotherapy-Induced Nausea and Vomiting • Hematological Malignancies • Leukemia • Lymphoma • Pediatrics • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • T-cell Acute Lymphoblastic Lymphoma

Aprepitant and fosaprepitant as a prophylactic antiemetic for preventing postoperative nausea and vomiting after general anaesthesia: a systematic review and meta-analysis. (PubMed, Clinics (Sao Paulo)) - "Aprepitant reduces the incidence of postoperative nausea, vomiting and the use of rescue antiemetics and increases the complete response rate among adult patients from 0 to 24 hours after surgery. Fosaprepitant reduces the incidence of vomiting from 0 to 24 hours after surgery. Findings primarily reflect female patients; male applicability requires further study."

Journal • Retrospective data • Review • Anesthesia

Prevention of Postoperative Nausea and Vomiting with Intravenous Fosaprepitant in Patients Undergoing Bariatric Surgery (ASA 2025) - "Our findings revealed that the incidence of postoperative nausea in patients who received fosaprepitant was significantly lower compared to patients who received ondansetron and dexamethasone alone (17.7% vs. 39.7%, p<0.0001). Therefore, fosaprepitant may indirectly reduce the risk of QT-prolongation and related side effects, since patients would no longer require as many rescue doses. Future prospective, randomized controlled trials that further explore the efficacy of fosaprepitant in prevention of PONV and its influence on related outcomes, such as hospital readmissions and patient satisfaction, are warranted."

Bariatric surgery • Clinical • Surgery • Anesthesia

Breast Cancer‒Associated Allergy Caused by Fosnetupitant-A Report of Four Cases (PubMed, Gan To Kagaku Ryoho) - "We describe the cases of 4 patients with breast cancer who developed an allergy to fosnetupitant (Pro‒NETU). The patients in cases 2, 3, and 4 had known allergies to docetaxel, and the cause of allergy in case 4 was unknown. Polysorbate 80, contained in docetaxel, fosaprepitant, and Pro‒NETU, was suspected to be the cause of allergy in cases 1, 2, and 3."

Journal • Allergy • Breast Cancer • Cardiovascular • Immunology • Oncology • Pulmonary Disease • Solid Tumor

Fosaprepitant Dimeglumine Alleviates Dengue Virus Infection and Virus-Induced Inflammatory Responses. (PubMed, ACS Infect Dis) - "For the first time, we report that fosaprepitant dimeglumine significantly suppressed the levels of the proinflammatory cytokines IL-6 and IP-10 in differentiated THP-1 macrophages infected with DENV-2. Fosaprepitant dimeglumine not only effectively inhibits DENV replication but also attenuates virus-induced inflammatory responses, which makes it a promising candidate for drug repurposing in the treatment of severe dengue."

Journal • Dengue Fever • Infectious Disease • Inflammation • IFNG • IL6

Cannabinoid Hyperemesis Syndrome Treated With Fosaprepitant: A Case Report. (PubMed, Cureus) - "The usual treatment options for nausea and vomiting include fluids and a combination of metoclopramide, ondansetron, promethazine, or prochlorperazine. We present a case where fosaprepitant was utilized for intractable nausea and vomiting when other treatment modalities failed for CHS."

Journal

Antiemetic drug fosaprepitant exerts anti-tumor effects against NSCLC by targeting FAK to inhibit AKT and JNK/c-Jun pathways. (PubMed, Acta Pharmacol Sin) - "Collectively, FOS exhibits significant anti-NSCLC activity both in vitro and in vivo by binding to FAK and inhibiting its phosphorylation, thereby blocking the AKT and JNK/c-Jun signaling pathways. These results suggest FOS as a novel FAK inhibitor for NSCLC treatment."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BARF RCT: Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide (clinicaltrials.gov) - P4 | N=212 | Not yet recruiting | Sponsor: Montefiore Medical Center | Initiation date: Jun 2025 ➔ May 2026 | Trial primary completion date: Mar 2026 ➔ Feb 2027 | Phase classification: P2/3 ➔ P4 | Trial completion date: Mar 2026 ➔ Feb 2027

Phase classification • Trial completion date • Trial initiation date • Trial primary completion date

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting (clinicaltrials.gov) - P2/3 | N=250 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: May 2025 ➔ Jun 2026 | Trial primary completion date: May 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date

Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting (clinicaltrials.gov) - P3 | N=126 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Xinxiang Medical College

New P3 trial • Chemotherapy-Induced Nausea and Vomiting • Solid Tumor

Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. (PubMed, Future Oncol) - "This individual patient data (IPD) meta-analysis compared the efficacy of NEPA (netupitant/fosnetupitant) and aprepitant/fosaprepitant-based regimens in preventing chemotherapy-induced nausea and vomiting (CINV)...A total of six studies involving 2,767 patients were included evaluating NEPA plus dexamethasone versus aprepitant/fosaprepitant plus any 5-HT3RA plus dexamethasone for patients with cancer receiving HEC/MEC. Complete response and no significant nausea rates were similar during the acute (0-24 h) phase but NEPA showed significantly higher rates than aprepitant during the delayed ( > 24-120 h) and overall (0-120 h) phases and on Days 3-5 following chemotherapy. Improved CINV prevention was observed with NEPA-based regimens, particularly during Days 3-5, highlighting its potential for managing prolonged nausea and vomiting associated with emerging anticancer targeted therapies."

CINV • Journal • Retrospective data • Review • Chemotherapy-Induced Nausea and Vomiting • Oncology

Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) (clinicaltrials.gov) - P2 | N=95 | Recruiting | Sponsor: Helsinn Healthcare SA | Not yet recruiting ➔ Recruiting

Enrollment open • Chemotherapy-Induced Nausea and Vomiting • Oncology • Pediatrics

QLM2010-301: To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. (clinicaltrials.gov) - P3 | N=664 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P3 trial • Chemotherapy-Induced Nausea and Vomiting

Aprepitant: Review on Solubility Enhancement. (PubMed, Recent Adv Drug Deliv Formul) - "The available solubility enhancement techniques discussed come with benefits and limitations. Fosaprepitant, a prodrug, is preferably used as an IV dosage form. Similarly, modification to a prodrug and solubility-enhancing excipients for nanoformulation can help make APT a promising therapy."

Journal • Chemotherapy-Induced Nausea and Vomiting • Oncology

Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting. (PubMed, Front Med) - "This article summarizes the available clinical and real-world data on the use of NK1RAs in CINV prophylaxis, with a focus on evidence from China, where three NK1RAs, aprepitant, fosaprepitant and netupitant, are currently approved. NK1RAs have demonstrated efficacy and favorable safety in the prevention of acute and delayed CINV. Further research is required to determine the optimal use of these drugs and to identify strategies for CINV management in specific patient populations."

CINV • Journal • Review • Chemotherapy-Induced Nausea and Vomiting

Fosaprepitant for the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. (PubMed, BMC Pharmacol Toxicol) - P4 | "Fosaprepitant plus triple therapy demonstrated superiority over triple therapy alone for CINV control in patients receiving three-day cisplatin-based treatment."

CINV • Clinical • Journal • Chemotherapy-Induced Nausea and Vomiting

Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial. (PubMed, Lancet Oncol) - "Post-chemotherapy administration of 5 mg olanzapine in combination with triplet antiemetic therapy before anthracycline plus cyclophosphamide-based chemotherapy significantly improved the complete response rate for chemotherapy-induced nausea and vomiting during the overall phase compared with placebo in female patients with breast cancer receiving outpatient chemotherapy, with an acceptable level of safety. The findings represent a substantial advancement in managing chemotherapy-induced nausea and vomiting and provide assurance that the safe and effective administration of olanzapine can be achieved at a dosage of 5 mg."

Journal • P3 data • Anesthesia • Anorexia • Breast Cancer • Chemotherapy-Induced Nausea and Vomiting • Constipation • Gastroenterology • Gastrointestinal Disorder • Oncology • Solid Tumor

A retrospective study on potential cross-reactivity between hypersensitivity reactions to taxanes and fosaprepitant. (ASCO 2025) - "Notably, only 34 of these patients were treated with albumin-bound paclitaxel as their subsequent treatment and all of them tolerated it well. HSRs to fosaprepitant are rare, and reactions to both fosaprepitant and taxanes are even rarer. Patients with fosaprepitant HSRs are more likely to develop taxane HSRs and vice versa. This increased HSR rate was seen with both paclitaxel and docetaxel groups and patients with taxane HSRs had a higher prevalence of prior allergies."

Retrospective data • Immunology • Oncology

Efficacy and safety of oral NEPA versus fosaprepitant combined with palonosetron for preventing highly emetogenic chemotherapy-induced nausea and vomiting in patients with nasopharyngeal carcinoma. (ASCO 2025) - "Funded by Prognostic evaluation and individualized treatment strategies for nasopharyngeal carcinoma based on recursive attention mechanisms (RAMs) and multimodal deep learning, Study of the antitumor effect of marine docosahexaenoic acid on the miR-26a/EZH2 axis in NSCLC, A non-inferiority, parallel design, randomized controlled study of saperine versus dexamethasone nebulized inhalation in the prevention and treatment of radiation oral mucositis in nasopharyngeal carcinoma Background: Oral NEPA, a fixed combination of netupitant (300 mg) and palonosetron (0.5 mg), is a highly effective antiemetic agent used in patients with cancer undergoing highly emetogenic chemotherapy (HEC)...156 patients (Oral NEPA group) received a single dose of NEPA capsules orally 1 hour before each chemotherapy cycle, while 156 patients (APR + PALO group) received once intravenous drip of FosAPR (150 mg) for 30 minutes followed by once intravenous injection of PALO (0.25 mg). In addition,..."

CINV • Clinical • Chemotherapy-Induced Nausea and Vomiting • Constipation • Gastroenterology • Gastrointestinal Disorder • Lung Cancer • Mucositis • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • Stomatitis • MIR26A1

Fosaprepitant Use as an Antiemetic to Prevent Postoperative Nausea and Vomiting in Pediatric Spinal Fusion Patients May Be Associated With More Rapid Transition to Oral Pain Medication and Reduced Length of Stay. (PubMed, J Pediatr Soc North Am) - "(1)Spinal fusion surgery patients are at risk of having significant postoperative nausea and vomiting.(2)Fosaprepitant is an effective agent to treat postoperative nausea and vomiting in adults, but has not been extensively studied in pediatrics for this purpose. The level of evidence is a 3 as it is a cohort study looking at the relationship between an exposure and an outcome."

Journal • Anesthesia • Pain • Pediatrics

The Role of Substance P in Corneal Homeostasis. (PubMed, Biomolecules) - "Emerging therapies targeting SP pathways- such as NK1R antagonists (e.g., fosaprepitant) and SP-IGF-1 combinations-show promise for treating neurotrophic ulcers but face challenges due to SP's context-dependent actions. Future research should clarify the roles of NK2R/NK3R receptors and optimize SP-based interventions to balance its reparative and inflammatory effects. Understanding SP's multifaceted mechanisms could advance the development of therapies for corneal diseases, particularly those involving sensory neuropathy and immune dysregulation."

Journal • Review • Dry Eye Disease • Inflammation • Keratitis • Ocular Inflammation • Ophthalmology • Pain • IGF1

Physiologically based pharmacokinetic modeling supports investigation of potential drug-drug interactions in the pre- and early post-hematopoietic stem cell transplantation stages. (PubMed, Front Pharmacol) - "PBPK models were developed and evaluated for 13 drugs commonly used in HSCT, including cyclosporine, tacrolimus, sirolimus, busulfan, phenytoin, voriconazole, posaconazole, itraconazole, fluconazole, letermovir, fosaprepitant, aprepitant, and omeprazole. This PBPK modeling platform provides a robust tool for identifying and mitigating DDIs in the pre- and early post-HSCT phases. By enabling the optimization of treatment regimens, this model serves as a valuable tool for improving drug safety and therapeutic outcomes for patients with HSCT."

Journal • PK/PD data • Bone Marrow Transplantation • Transplantation

Fosaprepitant use Post-Transplant in a Pediatric HCT Cohort: A Descriptive Analysis (ASPHO 2025) - "In addition to fosaprepitant, patients were on a median of 3 (range 1–4) additional scheduled antiemetics, with all patients on a concomitant 5HT3 receptor antagonist and 15/20 (75%) on concomitant olanzapine. In this descriptive analysis of 20 pediatric patients, fosaprepitant use post-HCT was well-tolerated and, in most patients, appeared to be associated with positive nausea/vomiting control. Any potential interaction with tacrolimus was manageable, with average tacrolimus level largely within goal range while on fosaprepitant. Post-transplant fosaprepitant warrants prospective study to further characterize its impact on nausea/vomiting control after allogeneic HCT."

Clinical • Post-transplantation • Chemotherapy-Induced Nausea and Vomiting • Pediatrics • Transplantation